37 related articles for article (PubMed ID: 26190396)
1. Search for Pompe disease among patients with undetermined myopathies.
Lindberg C; Anderson B; Engvall M; Hult M; Oldfors A
Acta Neurol Scand; 2016 Feb; 133(2):131-135. PubMed ID: 26190396
[TBL] [Abstract][Full Text] [Related]
2. Author Correction: Degeneration of muscle spindles in a murine model of Pompe disease.
Watkins B; Schultheiß J; Rafuna A; Hintze S; Meinke P; Schoser B; Kröger S
Sci Rep; 2024 Jun; 14(1):13394. PubMed ID: 38862583
[No Abstract] [Full Text] [Related]
3. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient.
Sato Y; Kobayashi H; Higuchi T; Shimada Y; Era T; Kimura S; Eto Y; Ida H; Ohashi T
Mol Ther Methods Clin Dev; 2015; 2():15023. PubMed ID: 26199952
[TBL] [Abstract][Full Text] [Related]
4. Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
Harmatz P
Clin Ther; 2015 Sep; 37(9):2130-4. PubMed ID: 26243075
[TBL] [Abstract][Full Text] [Related]
5. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
Rafael Bretón Martínez J; Martínez AC
J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
[No Abstract] [Full Text] [Related]
6. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
[TBL] [Abstract][Full Text] [Related]
7. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
Schuller Y; Hollak CE; Biegstraaten M
Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
[TBL] [Abstract][Full Text] [Related]
8. Inherited metabolic disorders: prenatal diagnosis of lysosomal storage disorders.
Verma J; Thomas DC; Sharma S; Jhingan G; Saxena R; Kohli S; Puri RD; Bijarnia S; Verma IC
Prenat Diagn; 2015 Nov; 35(11):1137-47. PubMed ID: 26223439
[TBL] [Abstract][Full Text] [Related]
9. Late onset form of Pompe disease.
Mattosova S; Hlavata A; Spalek P; Kotysova L; Macekova D; Chandoga J
Bratisl Lek Listy; 2015; 116(8):502-5. PubMed ID: 26350092
[TBL] [Abstract][Full Text] [Related]
10. Lyso-Gb3 activates Notch1 in human podocytes.
Sanchez-Niño MD; Carpio D; Sanz AB; Ruiz-Ortega M; Mezzano S; Ortiz A
Hum Mol Genet; 2015 Oct; 24(20):5720-32. PubMed ID: 26206887
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).
Saito O; Kusano E; Akimoto T; Asano Y; Kitagawa T; Suzuki K; Ishige N; Akiba T; Saito A; Ishimura E; Hattori M; Hishida A; Guili C; Maruyama H; Kobayashi M; Ohashi T; Matsuda I; Eto Y
Clin Exp Nephrol; 2016 Apr; 20(2):284-93. PubMed ID: 26197777
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing detection of late onset pompe disease.
Angelini C; Savarese M; Fanin M; Nigro V
Muscle Nerve; 2016 Jun; 53(6):981-3. PubMed ID: 26800218
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic Pompe disease: Can muscle magnetic resonance imaging facilitate diagnosis?
Pichiecchio A; Berardinelli A; Moggio M; Rossi M; Balottin U; Comi GP; Bastianello S
Muscle Nerve; 2016 Feb; 53(2):326-7. PubMed ID: 26474166
[No Abstract] [Full Text] [Related]
14. A conceptual disease model for adult Pompe disease.
Kanters TA; Redekop WK; Rutten-Van Mölken MP; Kruijshaar ME; Güngör D; van der Ploeg AT; Hakkaart L
Orphanet J Rare Dis; 2015 Sep; 10():112. PubMed ID: 26374742
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.
Goker-Alpan O; Gambello MJ; Maegawa GH; Nedd KJ; Gruskin DJ; Blankstein L; Weinreb NJ
JIMD Rep; 2016; 25():95-106. PubMed ID: 26303609
[TBL] [Abstract][Full Text] [Related]
16. Giant Heart of Classical Infantile-Onset Pompe Disease With Mirror Image Dextrocardia.
Tripathi SP; Phadke MS; Kerkar PG
Circ Cardiovasc Imaging; 2015 Sep; 8(9):e003637. PubMed ID: 26286728
[No Abstract] [Full Text] [Related]
17. Bioimpedance Analysis as a Method to Evaluate the Proportion of Fatty and Muscle Tissues in Progressive Myopathy in Pompe Disease.
Różdżyńska-Świątkowska A; Jurkiewicz E; Tylki-Szymańska A
JIMD Rep; 2016; 26():45-51. PubMed ID: 26253708
[TBL] [Abstract][Full Text] [Related]
18. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study.
Wencel M; Shaibani A; Goyal NA; Dimachkie MM; Trivedi J; Johnson NE; Gutmann L; Wicklund MP; Bandyopadhay S; Genge AL; Freimer ML; Goyal N; Pestronk A; Florence J; Karam C; Ralph JW; Rasheed Z; Hays M; Hopkins S; Mozaffar T
Neurol Genet; 2021 Dec; 7(6):e623. PubMed ID: 36299500
[TBL] [Abstract][Full Text] [Related]
19. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
20. Secondary myopathy due to systemic diseases.
Finsterer J; Löscher WN; Wanschitz J; Quasthoff S; Grisold W
Acta Neurol Scand; 2016 Dec; 134(6):388-402. PubMed ID: 26915593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
